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ABSTRACT
Objectives Women attending STI clinics are not routinely 
tested for oropharyngeal Chlamydia trachomatis (CT) 
infections. We aimed to assess spontaneous clearance of 
oropharyngeal CT and cure after antibiotic treatment in 
women.
Methods Women with vaginal or rectal CT (n=560) 
were recruited at STI clinics in 2016–2017, as part 
of the FemCure study (prospective cohort study). We 
included participants’ data from week −1, that is, the 
diagnosis at initial visit, when clinics applied selective 
oropharyngeal testing. At week −1, a total of 241 women 
were oropharyngeally tested (30 positive) and 319 were 
untested. All FemCure participants provided nurse- collected 
oropharyngeal samples at study enrolment, that is, week 
0, just prior to treatment (n=560), and after treatment at 
weeks 4 (n=449), 8 (n=433) and 12 (n=427). Samples 
were tested by nucleic acid amplification test, and at week 
0 also by viability testing by viability PCR. Proportions of 
oropharyngeal CT test results were presented to represent 
spontaneous clearance and cure.
Results Of 30 women diagnosed with oropharyngeal 
CT at week −1, fifteen (50%) were negative at week 0 
after a median of 9 days, that is, ’spontaneous clearance’. 
At week 0, a total of 560 participants were tested, and 
46 (8.8%) were oropharyngeal CT positive; 12 of them 
(26.1%) had viable CT. Of the 46 positive, 36 women had 
an oropharyngeal test after treatment; 97.2% (35/36) 
were negative at week 4, that is, ’cure’. Of all women 
with follow- up visits, the proportion of oropharyngeal CT 
positive was between 0.5% and 1.6% between weeks 4 
and 12. Of those not tested at week −1 (n=319), 8.5% 
(n=27) were oropharyngeal positive at week 0.
Conclusions The clinical importance of oropharyngeal CT 
in women is debated. We demonstrated that spontaneous 
clearance of oropharyngeal CT among women is common; 
of those who did not clear for CT, three- quarters had 
non- viable CT. After regular treatment with azithromycin 
or doxycycline, cure rate (97%) of oropharyngeal CT is 
excellent.
Trial registration number NCT02694497.
INTRODUCTION
Chlamydia trachomatis (CT) infection is the most 
commonly reported treatable bacterial STI in high- 
income countries.1 2 CT disproportionally affects 
women, who may develop pelvic inflammatory 
disease, ectopic pregnancy, tubal infertility and 
chronic abdominal pain.3 4 CT can occur at the 
vaginal site, the rectal site and the oropharyngeal 
site. The prevalence of oropharyngeal CT is 0.2%–
3.2% (median 1.7%) in women, 0%–3.6% (median 
1.7%) in men who have sex with men (MSM) 
and 0%–22.0% (median 1.6%) among men who 
have sex with women.5 Oropharyngeal CT may 
frequently occur as a single infection (thus without 
genital or rectal CT); this was the case in 53% of 
148 MSM and 32% of 164 women, selectively 
tested, at the STI clinic in Amsterdam.6 Data on 
oropharyngeal CT in women are scarce as women 
are not routinely tested for oropharyngeal CT, 
while in MSM oropharyngeal testing is an emerging 
practice.5 Oropharyngeal CT infections have been 
considered low bacterial load infections7 that are 
frequently self- limiting.6 8 Concerns were raised that 
oropharyngeal CT infection may initiate a reservoir 
of infection, that is, via the gastrointestinal tract.9 
To date, the role of oropharyngeal CT in further CT 
transmission or in the capacity to cause clinically 
relevant infections is unclear, and thereby the need 
for oropharyngeal testing in women is debated.10
As part of the FemCure study,11 we followed 
women diagnosed with vaginal or rectal CT in 
routine STI clinic care, and have taken the opportu-
nity to also assess oropharyngeal CT over time. We 
evaluated clearance of oropharyngeal CT between 
diagnosis and treatment (ie, spontaneous clear-
ance), clearance of oropharyngeal CT at 4 weeks 
after treatment (ie, cure) and the occurrence of 
oropharyngeal CT up to 12 weeks after regular 
treatment for rectal or vaginal CT. In addition, next 
to assessing CT- DNA positivity, we assessed the CT 
viability.
METHODS
Study design
This is a prospective cohort study, as part of the 
FemCure study.11 The study was conducted at three 
STI clinics of the Public Health Services South 
Limburg, Rotterdam- Rijnmond and Amsterdam, 
which together conduct almost half of all STI clinic 
consultations in the Netherlands. We include data 
from participants’ clinic diagnosis visit, before 
enrolment at week −1, when selective oropharyn-
geal testing was applied per routine care protocol; 
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based on being a sex worker, being notified or orally exposed as 
indication for oropharyngeal testing, as oropharyngeal screening 
is not standardly recommended in women.12 13 Oropharyngeal 
tested women, in most cases, reported unprotected sex with 
a casual partner. Clinics applied the same procedures using 
different nucleic acid amplification tests (NAAT) with compa-
rable high sensitivity for diagnostic testing.13 Women who, at 
week −1, were diagnosed with a vaginal or a rectal CT infection 
between April 2016 and September 2017 could be included in 
the study, at week 0, when they returned to the clinic for treat-
ment, on the day of and just prior to treatment. Treatment was 
according to regular care protocol12; that is, either by a 7- day 
course of doxycycline 100 mg orally twice daily or a 1 g single 
oral dose of azithromycin; treatment choice was not based on the 
oropharyngeal CT test result. At study enrolment, at STI clinic 
visits at week 0, just prior to treatment for vaginal or rectal CT, 
and at weeks 4, 8 and 12 after treatment, study nurses collected 
oropharyngeal samples (swab) from participants. As these study 
samples were tested afterwards, participants were untreated 
for oropharyngeal CT during follow- up. At week 12, women 
received a routine STI clinic check- up including oropharyngeal 
testing and treatment when needed. Some women became lost to 
follow- up (figure 1).
Sample processing
Two swabs were collected at week 0. A first sample was collected 
for viability testing and a second sample was collected for 
CT- DNA testing. The sample for viability testing was placed in 
4 mL sucrose phosphate transport buffer and immediately stored 
at −80°C to maintain CT viability until laboratory analysis. 
The sample for CT- DNA testing was placed in COBAS buffer 
and used to test for CT- DNA with PCR (Roche Cobas 4800, 
Roche Diagnostics, Basel, Switzerland), according to manufac-
turers’ guidelines. Second, swabs were placed in COBAS buffer 
for testing with quantitative PCR testing, detecting CT- DNA 
(Roche Cobas 4800, Roche Diagnostics), according to manufac-
turers’ guidelines. Of the women who tested positive in NAAT 
at week 0, samples were subsequently tested for viability with 
viability PCR (V- PCR). A positive V- PCR test indicates presence 
of CT- DNA from intact (ie, viable) CT organisms.14 15 Week 4, 8 
and 12 samples were tested by NAAT.
Definitions and statistical analyses
Spontaneous clearance: when a woman was diagnosed by NAAT 
with oropharyngeal CT at week −1, and tested negative by 
NAAT for oropharyngeal CT when she returned for treatment 
at week 0.
Cure: when a woman who tested positive by NAAT for 
oropharyngeal CT at week 0, just prior to treatment, tested 
oropharyngeal CT negative by NAAT at week 4 after treatment.
We present spontaneous clearance and cure as proportions. 
We also present the test results at each study visit, and viability 
test result at week 0 as proportions. We used SPSS Statistics V.24 
(IBM) for descriptive statistics.
RESULTS
At week −1, five hundred and thirty- one women were diag-
nosed with vaginal CT and 184 with rectal CT. Two hundred and 
forty- one women were also tested for oropharyngeal CT and 30 
women were diagnosed with oropharyngeal CT. Three hundred 
and nineteen women were not oropharyngeal tested (figure 1). 
Median age was 22 years (IQR was 20–24).
Spontaneous clearance between clinic diagnosis at week −1 
and treatment at week 0
The median interval between the week −1 and week 0 visits was 
9 days (IQR: 7–12). In the 30 women diagnosed with oropha-
ryngeal CT at week −1, spontaneous clearance at week 0 was 
observed in 15 (50% (95% CI 31.3% to 68.7%)) (table 1).
Cure at week 4 post-treatment
Of the 46 women who were CT positive at week 0, thirty- six 
were tested at week 4. Cure (ie, NAAT negative at week 4) was 
observed in 35 (97.2% (95% CI 85.5% to 99.9%)) (table 2). 
Cure was 93.8% (15/16) in the women who received azithro-
mycin and 100% (20/20) in the women who received doxycy-
cline (exact test p=0.444).
Oropharyngeal CT and viability before treatment (week 0)
At week −1, two hundred and forty- one women were oropha-
ryngeally tested and n=30 (12.4%) tested positive for oropha-
ryngeal CT. Of the n=30 women diagnosed with oropharyngeal 
CT at week −1, n=15 were oropharyngeal CT positive at the 
subsequent visit at week 0 (table 1). Of the 211 women who 
tested negative at week −1, n=4 (1.9%) were oropharyngeally 
positive at week 0. Of the 319 women who were oropharyn-
geally untested at week −1, n=27 (8.5%) were oropharyngeally 
CT positive at week 0.
Thus, at week 0, in total 46 (8.8%) women were oropharyn-
geal CT positive. Of these, 26.1% (12/46) had viable CT, that is, 
tested V- PCR positive. Of the 12 women with viable CT at week 
0, one tested CT oropharyngeal positive at week 4 by NAAT; in 
fact she also tested positive at weeks 8 and 12.
Figure 1 Design of the study and number of participants at each time point. CT, Chlamydia trachomatis; Ph, oropharyngeal.
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Oropharyngeal CT after treatment at weeks 4, 8 and 12
Ten women had an oropharyngeal CT positive test after treat-
ment. One woman was positive at all post- treatment visits; she 
reported receptive oral sex during complete follow- up. Nine 
women were positive at a single time point only; n=2 at week 4, 
n=1 at week 8, n=6 at week 12 visit. The proportion of oropha-
ryngeal CT positive was between 0.5% and 1.6% between weeks 
4 and 12 (table 2).
DISCUSSION
This is the first prospective study in women evaluating the 
trajectory of oropharyngeal CT infections from diagnosis to 
pretreatment, and until 12 weeks after treatment. We assessed 
spontaneous clearance and cure after standard treatment for 
anogenital CT infections, in women attending Dutch STI clinics.
Spontaneous oropharyngeal CT clearance was 50% (95% 
CI 31.3% to 68.7%) after a median of 9 days after diagnosis 
of oropharyngeal CT in 30 women. This is similar to results in 
seven women showing 57.1% with a median follow- up of 10 
days,8 and slightly higher than the 36.4% observed using RNA- 
based testing in 55 women in a median follow- up of 9 days.6 
The proportion of spontaneous clearance of oropharyngeal 
CT is much higher than we observed for vaginal CT (6.0%, 
95% CI 4.2% to 8.4%) and rectal CT (15.8%, 95% CI 10.8% to 
21.8%).16 A possible explanation is the lower initial CT bacte-
rial load at the oropharyngeal site compared with the vaginal 
and the rectal site,7 because lower initial load is associated with 
oropharyngeal CT clearance.6 8 Of those women who remained 
CT positive at the oropharyngeal site at week 0, three quarters 
had non- viable CT only.
Cure was high for both azithromycin and doxycycline. Four 
weeks after treatment, 97.2% of women were negative for 
oropharyngeal CT. Proportions of cure were similar to those 
in azithromycin- treated vaginal CT (93.5% (95% CI 90.1% to 
96.1%)), in doxycycline- treated vaginal CT (95.4% (95% CI 
90.9% to 98.2%)) and in doxycycline- treated rectal CT (95.5% 
(95% CI 91.0% to 98.2%)); and higher than in azithromycin- 
treated rectal CT (78.5% (95% CI 72.6% to 83.7%)).17 One 
woman was positive at all follow- up visits until week 12; she had 
oropharyngeal viable CT at week 0 and was untested at week 
−1; she reported receptive oral sex during follow- up.
A substantial proportion (8.5%) of women with vaginal or 
rectal CT, and who were not tested at the oropharynx at week 
−1, turned out to have oropharyngeal CT (at week 0), of whom 
almost a third had viable CT. Since vaginal CT is a risk factor 
for having oropharyngeal CT,6 the proportion of all women 
attending STI clinics with oropharyngeal CT may be lower than 
observed in this study. Phillips et al showed among MSM with 
oropharyngeal chlamydia, that nearly three- quarters had chla-
mydia DNA detected in saliva, but viability was not assessed.18 
The proportion of positive women with viable oropharyngeal 
CT was 26.1% (12/46), which is lower than proportions of 
viable CT that we observed in vaginally (94.0%–96.4%) and 
in rectally CT- infected women (58.0%–66.5%).17 Although the 
proportion with viable oropharyngeal CT is relatively small, it 
may represent relevant infections for ongoing transmission to a 
sexual partner via oral sex,19 but possibly also to the own rectal 
site, via the gastrointestinal canal.20 After treatment, following 
>425 women until week 12, only few women tested positive 
and most only at a single time point. The proportion of positive 
after treatment was between 0.5% and 1.6%, in line with the 
estimated proportion of oropharyngeal CT in women (0.2%–
3.2%; median 1.7%).5
In regular care practice, oropharyngeal CT testing is not 
routinely performed. Thus, oropharyngeal single- site CT infec-
tions (ie, without concurrent vaginal or rectal infection) largely 
remain untreated in women. Our study did not include partic-
ipants with single oropharyngeal CT at week −1, precluding 
analyses on single infections. However, single- site oropharyn-
geal CT spontaneous clearance has previously been found higher 
than concomitant oropharyngeal CT infections,6 possibly due to 
lower initial bacterial load.8 Still, in the STI clinic female popu-
lation, part of the women with oropharyngeal CT will have 
vaginal CT. These women are standard tested for vaginal CT, 
and treated when positive, thereby as well treating a possible 
concurrent oropharyngeal CT. Altogether, the current study 
does not provide support for routine oropharyngeal CT testing 
in women who are already being tested for vaginal (or rectal) 
infection.
Table 1 Proportions of oropharyngeal CT test results at week 0 
(enrolment, just prior to treatment) by the preceding week −1 clinic 
diagnoses (interval 9 days) in 560 women, FemCure
Week −1 (clinic diagnosis)
Week 0 (enrolment, treatment)
PhCT− PhCT+
n (%) n (%)
Total: n=560 514 (91.8) 46 (8.2)
  PhCT+ (n=30) 15 (50.0)* 15 (50.0)
  PhCT− (n=211) 207 (98.1) 4 (1.9)
  PhCT untested (n=319) 292 (91.5) 27 (8.5)
*Indicates proportion of spontaneous clearance.
CT, Chlamydia trachomatis; Ph, oropharyngeal; PhCT+/−, oropharyngeal positive or 
negative test result.
Table 2 Proportions of oropharyngeal test results after regular treatment at weeks 4, 8 and 12 by the preceding week 0 (enrolment, just prior to 
treatment) test result, FemCure
Week 0 (enrolment, 
pretreatment)#
Tested at 
week 4
Week 4: 
PhCT−
Week 4: 
PhCT+
Tested at 
week 8
Week 8: 
PhCT−
Week 8: 
PhCT+
Tested at 
week 12
Week 12: 
PhCT−
Week 12: 
PhCT+
N n (%) n (%) N n (%) n (%) N n (%) n (%)
Total 449 446 (99.3) 3 (0.7)a 433 431 (99.5) 2 (0.5)a 427 420 (98.4) 7 (1.6)b
  PhCT− (n=514) 413 411 (99.5) 2 (0.5)a 397 396 (99.5) 1 (0.5)a 391 386 (98.7) 5 (1.3)c
  PhCT+ (n=46) 36 35 (97.2)* 1 (2.8)a 36 35 (97.2) 1 (2.8)a 36 34 (94.4) 2 (5.6)c
a: All reported recent (receptive) oral sex.
b: n=5 reported recent (receptive) oral sex.
c: n=1 reported recent (receptive) oral sex.
*Indicates ‘cure’.
CT, Chlamydia trachomatis; Ph, oropharyngeal; PhCT+/−, oropharyngeal positive or negative test result.
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This study has several limitations. (1) As in all human clear-
ance studies, the moment of infection was unknown. (2) The 
exact day of clearance or cure is unknown, because we did 
not collect daily samples. (3) Clearance may differ by geno-
type,21 22 but genotyping was not performed on the diagnosis, 
at the week −1, study samples. Genotyping would also be valu-
able to exclude reinfections, if these were with other genotypes. 
(4) Possibly, using a one time point test to assess spontaneous 
clearance or cure could have resulted in detecting false- negative 
or false- positive results.23–25 ‘On off effects’ (ie, a positive and 
negative test result in the same sample) might occur in samples 
with a low bacterial load around the detection limit, which may 
be more often the case in oropharyngeal CT infections. (5) The 
representativeness of our study is unknown. In the FemCure 
study, women with high education, women without a history of 
STI and non- Western migrant women were under- represented 
compared with all STI clinic women with CT infection.26 Also, 
STI clinic populations may not represent the general population.
To conclude, this study contributes to the growing knowledge 
on oropharyngeal CT. Most women diagnosed with vaginal 
or rectal chlamydia are not tested for CT in the oropharynx; 
yet 8.5% of these women tested NAAT positive for CT in the 
oropharynx when returning for CT treatment. However, we 
demonstrate that spontaneous clearance of oropharyngeal CT is 
substantial and higher than what is known for vaginal or rectal 
CT. The cure rate after regular treatment for anorectal CT infec-
tions is very high, and similar to that for vaginal CT. Our data 
suggest that routine universal oropharyngeal CT testing in all 
women, who are already tested for vaginal (or rectal CT), is of 
questionable importance.
Key messages
 ► Most women diagnosed with vaginal or rectal chlamydia are 
not tested for Chlamydia trachomatis (CT) in the pharynx; 
8.5% of these women tested nucleic acid amplification test 
(NAAT) positive for CT in the oropharynx.
 ► Of women who tested NAAT positive for CT in the 
oropharynx, 26.1% had viable CT.
 ► Fifty per cent of women tested NAAT positive for chlamydia 
(CT) in the oropharynx were negative after a median 9 days, 
indicating spontaneous clearance.
 ► Nearly all (97.2%) women tested NAAT positive for CT in the 
oropharynx cleared CT 4 weeks after receiving azithromycin 
or doxycycline.
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